文献速递脊柱关节炎

银屑病患者接受生物制剂治疗与银屑病关节炎发生率:巢式病例对照研究

Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study.
PubMed 文献 · Arthritis Rheumatol · 2021-12-21

该回顾性队列研究基于大型健康维护组织电子病历,纳入1,326例银屑病患者(663例接受生物制剂,663例未接受),经倾向性评分匹配后比较银屑病关节炎(PsA)发生风险。Kaplan-Meier曲线显示对照组PsA风险显著高于生物制剂组;多变量Cox回归显示随访10年内对照组PsA风险显著更高(校正HR 1.39,95%CI 1.03-1.87)。结论提示生物制剂治疗与PsA发生风险降低相关。

要点

  • 接受生物制剂治疗的银屑病患者10年内PsA风险显著低于未接受者(校正HR 1.39)。
  • 研究采用倾向性评分匹配控制年龄、性别、病程、BMI和吸烟状态等混杂因素。
  • 结果提示对具有PsA显著危险因素的患者可考虑早期使用生物制剂。

核心结论

  • 银屑病患者接受生物制剂治疗与PsA发生风险显著降低相关(校正HR 1.39,95%CI 1.03-1.87)。

研究设计与样本

  • 回顾性队列研究,基于大型健康维护组织电子病历,纳入1,326例银屑病患者(663例接受生物制剂,663例未接受),采用倾向性评分匹配后以Log rank检验和多变量Cox回归比较。

主要发现

  • 倾向性评分匹配后Kaplan-Meier曲线显示对照组PsA风险显著高于生物制剂组。
  • 多变量Cox回归显示随访10年内对照组PsA风险显著高于生物制剂组(校正HR 1.39,95%CI 1.03-1.87)。

临床怎么用

  • 对具有PsA显著危险因素的银屑病患者,可考虑在治疗早期使用生物制剂以降低PsA发生风险。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of biologic treatments for psoriasis on the incidence of psoriatic arthritis (PsA). METHODS: This retrospective cohort study was conducted using electronic medical records from a large health maintenance organization. Patients who received biologic treatment for psoriasis and were not diagnosed as having PsA before or at the time of biologic treatment initiation were included. Control psoriasis patients who did not receive biologic treatment were matched by age at time of diagnosis, sex, time from psoriasis diagnosis until treatment initiation, maximum body mass index, and smoking status. The groups were different in most characteristics. Therefore, propensity score matching was implemented. Log rank test and multivariable Cox proportional hazards regression were used to compare the groups. RESULTS: Overall, 1,326 patients were included, of whom 663 had received biologic treatment and 663 had not. The Kaplan-Meier curve for the propensity score-matched groups reflected a statistically significant increased risk for PsA among the control group compared to the biologic treatment group. The results of the multivariable Cox regression showed that the control group had a significantly higher risk for PsA compared to the biologic treatment group within 10 years of follow-up (adjusted hazard ratio 1.39 [95% confidence interval 1.03-1.87]). CONCLUSION: Our findings show a statistically and clinically significant decreased risk for developing PsA among patients with psoriasis who receive biologic treatments. The results suggest that biologic medications should be considered for patients who present with significant risk factors for PsA at an earlier stage of treatment.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rosenthal YS, Schwartz N, Sagy I, et al. Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study. Arthritis Rheumatol. 2021. PMID: 34423909. doi:10.1002/art.41946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。